<DOC>
	<DOCNO>NCT00028587</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine PS-341 combination chemotherapy treat patient advance solid tumor . PS-341 may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining PS-341 chemotherapy may kill tumor cell</brief_summary>
	<brief_title>PS-341 Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose bortezomib paclitaxel administer combination carboplatin patient advance solid tumor . II . Compare tolerability efficacy different sequence regimen patient . III . Determine clinical toxic effect pharmacokinetics regimen patient . IV . Determine , preliminarily , therapeutic activity regimen patient . V. Evaluate p53 accumulation marker PS-341 activity , effect paclitaxel/carboplatin PS-341 induced accumulation p53 . VI . Exam effect PS-341 level proteasome target , e.g . mdm2 , p27 , p21 , cyclins B , D1 , E ; IÎºB ubiquitinated protein tumor tissue , available . OUTLINE : This dose-escalation study bortezomib paclitaxel . Patients assign 1 2 treatment group . Group A : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 bortezomib IV 3-5 second day 2 , 5 , 8 . Group B : Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 paclitaxel IV 3 hour carboplatin IV 30 minute day 2 . Treatment group repeat every 3 week absence disease progression unacceptable toxicity . After 6 course paclitaxel carboplatin , patient stable respond disease may continue bortezomib alone discretion investigator . Cohorts 3-6 patient group receive escalate dos bortezomib paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow 3 month . PROJECTED ACCRUAL : A total 24-96 patient accrue study within 25 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Histologically confirm malignancy know standard therapy potentially curative definitely capable extend life expectancy exist No hematologic malignancies No symptomatic CNS metastasis Brain metastasis allow previously treat ( radiotherapy and/or surgery ) patient stable least 8 week Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 2.5 time ULN Creatinine great 1.5 time ULN No New York Heart Association class III IV heart disease HIV negative No peripheral neuropathy grade 2 great No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception More 4 week since prior biologic therapy More 4 week since prior immunotherapy No prior bone marrow transplantation No concurrent immunotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy More 4 week since prior radiotherapy No prior radiotherapy 30 % bone marrow No concurrent radiotherapy No concurrent investigational ancillary therapy No concurrent enrollment another study involve pharmacologic agent ( e.g. , drug , biologics , immunotherapy , gene therapy ) symptom control therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>